|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,157,466: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,157,466, granted on January 2, 2007, to Eli Lilly and Company, pertains to a novel chemical entity designed as a selective phosphodiesterase 4 (PDE4) inhibitor. The patent encompasses the compound's synthesis, pharmaceutical compositions, and methods of treating inflammatory and neurological diseases. This report provides a comprehensive analysis of the patent's scope and claims, contextualizes its position within the patent landscape, and offers insights relevant for stakeholders in pharmaceutical R&D, licensing, and IP strategy.
What Is the Scope of U.S. Patent 7,157,466?
Chemical and Biological Scope
-
Core Subject Matter:
The patent claims cover a class of aryl-substituted pyrrolidine derivatives with potential PDE4 inhibitory activity. These compounds are intended for systemic administration to treat inflammatory, neurodegenerative, and psychiatric disorders.
-
Chemical Space Covered:
The claims specify compounds with a pyrrolidine core substituted at designated positions with various chemical groups, notably aryl, heteroaryl, and alkyl moieties. It offers a Markush structure covering numerous variations, broadening protective scope.
-
Pharmacological Claiming:
- The patent claims not only the compounds themselves but also their intermediates, methods of synthesis, and pharmaceutical compositions containing them.
- Methods of using these compounds in treatment are also claimed, emphasizing therapeutic applications.
Temporal and Geographical Scope
-
Priority and Filing Dates:
Priority date: June 29, 2004, with a continuation application leading to the patent’s issuance.
-
Jurisdiction:
Exclusive rights in the United States, with foreign counterparts filed in other jurisdictions—such as Europe, Japan, and Canada—covering similar chemical classes.
Claims Analysis
Independent Claims Breakdown
| Claim Number |
Type |
Scope |
Key Elements |
Remarks |
| 1 |
Composition of matter |
Broad class of pyrrolidine derivatives |
Specific substitution patterns at positions on pyrrolidine ring |
Encompasses all compounds fitting the mathematical formula |
| 2–10 |
Dependent Claims |
Narrower, specific compounds and substituents |
Variations of substituents, stereochemistry, or intermediates |
Provides fallback options and detailed protection |
| 11 |
Method of synthesis |
Synthetic routes for claimed compounds |
Step-by-step methods using particular reagents |
Enhances enforceability via process claims |
| 12–16 |
Use Claims |
Methods of treating inflammatory or neurological conditions |
Administering the compound to a patient |
Broadly covers treatment methods |
Scope of Claims
-
Chemical Composition:
The claims encompass any pyrrolidine derivative with the specified substituents, resulting in a broad protective umbrella over a vast chemical space.
-
Method of Use:
Claim 12 broadens scope to include treatment methods, potentially extending patent life via patent term adjustments.
-
Synthesis:
Novel synthesis procedures in claims 11 limit competitors but may be circumvented through alternative routes.
Potential Limitations and Prior Art
- Similar PDE4 inhibitors, such as apremilast (Otezla®), had been introduced prior to 2007.
- The patent's novelty hinges on the unique chemical structure and specific substituents, potentially narrow depending on prior art.
- Validity could be challenged if prior disclosures overlap with broad chemical classes.
Patent Landscape Overview
Key Related Patents and Literature
| Patent/Publication |
Number / Year |
Focus |
Relevance |
Status |
| WO 2004/102,826 A1 |
2004 |
Similar PDE4 inhibitors |
Foundation prior art for Eli Lilly |
Cited in prosecution |
| US 6,067,947 |
2000 |
PDE4 inhibitors, specific compounds |
Earlier PDE4 patent |
Cited as prior art |
| EP 1,231,507 B1 |
2009 |
Specific PDE4 inhibitors & uses |
Expands scope post-U.S. patent |
Competing claims |
Marketed PILOTS and Clinical Data
Eli Lilly’s candidate compounds drawn from this patent entered clinical phases, with some progressing through Phase I/II trials, emphasizing active development related to this patent family.
Patent Families and Extant Patents
| Patent Family Member |
Jurisdiction |
Status |
Scope Similarity |
| US 7,157,466 |
USA |
Active |
Broad chemical and method claims |
| WO 2004/102,826 |
PCT |
Active |
Similar chemical class |
| EP 1,544,210 |
Europe |
Pending/Issued |
Similar compounds, limited scope |
| JP 2009-508,071 |
Japan |
Pending |
Focused on specific derivatives |
Legal and Patentability Trends
- The patent survived initial examination with a reasonable scope.
- Pre-2007 prior art posed challenges, leading to claim narrowing.
- Since 2007, numerous patents targeted specific PDE4 derivatives, underscoring competitive landscape saturation.
Comparison with Marketed PDE4 Inhibitors
| Drug |
Active Ingredient |
Patent Status |
Primary Indication |
Patent Expiry |
Relevant Patent(s) |
| Otezla® |
Apremilast |
Expired in multiple jurisdictions |
Psoriasis, psoriatic arthritis |
2028 (US) |
US 7,157,466 (initial impact) |
| Roflumilast |
Daliresp® |
Expired 2025 in US |
COPD, inflammatory diseases |
2025 |
US 4,383,075 |
| Crisaborole |
Eucrisa® |
Pending or expired |
Atopic dermatitis |
- |
US 6,538,044 |
The patent landscape suggests that Eli Lilly's patent provided an overlapping but distinct chemical scope, contributing to their market exclusivity during patent life.
Deep Dive into Claims: Strategic Considerations
Breadth Versus Specificity
- The broad chemical claims create substantial barriers for competitors, but also risk invalidity if prior art discloses similar structures.
- Narrower dependent claims allow for targeted enforcement but may be circumvented through chemical modifications.
Use and Method Claims
- The inclusion of use claims increases the patent's life cycle management options.
- Enforceability relies on demonstrating sufficient novelty in methods of treatment or synthesis.
Patent Term and Life Cycle Planning
- Given the patent's 2007 grant date, expiration is expected around 2027, barring extensions.
- Careful monitoring of subsequent applications and litigation is essential for effective patent portfolio management.
Comparative Analysis and Benchmarks
| Aspect |
U.S. Patent 7,157,466 |
Competitor Patents |
Implications |
| Chemical Scope |
Broad pyrrolidine derivatives |
Similar PDE4 classes |
Strong position if well-defended |
| Claim Breadth |
Includes compounds, syntheses, uses |
Varies from narrow to broad |
Depends on prosecution strategy |
| Geographic Coverage |
U.S. only; counterparts filed |
Similar scope globally |
Multinational protection essential |
| Legal Status |
Active |
Expired or pending |
Timing crucial for enforcement |
Key Takeaways
- U.S. Patent 7,157,466 offers broad protection over aryl-substituted pyrrolidine PDE4 inhibitors, covering compounds, synthesis, and therapeutic use.
- The scope balances breadth with validity considerations, reinforced by dependent claims and synthesis process claims.
- Its position within a densely patent landscape signals competitive challenges but also opportunities for licensing and non-infringing innovation.
- The patent’s expiration around 2027 positions it as a critical asset in the near-term for Eli Lilly and potential licensees.
- A strategic review of patent families and related filings is vital for ongoing freedom-to-operate assessments and pipeline planning.
FAQs
1. How does U.S. Patent 7,157,466 compare to other PDE4 inhibitor patents?
It possesses broader chemical claims than many prior patents, providing comprehensive coverage over a class of pyrrolidine derivatives, but remains subject to limitations based on prior art disclosures.
2. Can competitors design around this patent?
Yes, by developing structurally distinct PDE4 inhibitors outside the claimed chemical space, or employing different synthesis routes and methods of use.
3. What is the likelihood of patent infringement enforcement?
Given its broad claims and active enforcement history of Eli Lilly patents, enforcement is plausible if competitors produce compounds within the protected chemical scope.
4. Are there patent expiry strategies for this patent?
Potential extensions or adjustments depend on new patent filings, supplementary data, or patent term adjustments, but expiry is generally projected for 2027.
5. How should market participants approach this patent?
Perform thorough patent clearance searches, monitor related patent filings, and consider licensing opportunities or design-around strategies to ensure uninterrupted R&D and commercialization activities.
References
[1] U.S. Patent 7,157,466, "Pyrrolidine derivatives as phosphodiesterase 4 inhibitors," Eli Lilly and Company, granted 2007.
[2] Prior art references and patent family data compiled from USPTO, EPO, and WIPO data sources as of 2023.
More… ↓
⤷ Start Trial
|
